At her blog, Isis responds to a reader who sent her his CV which listed the funding he had applied for but did not receive. She likens it to listing all the people you've hit on, but turned you down — "It means nothing unless you seal the deal," Isis says. In her comments, PhysioProf points out that listing those items-in-progress, depending on the context, should actually be done.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.